Robert Schreiber, PH.D.

Alumni Endowed Professor of Pathology and Immunology, Professor of Molecular Microbiology, Director of the Center for Human Immunology and Immunotherapy programs, Washington University School of Medicine

A leader in the study of tumor immunology, Bob Schreiber is a senior scientific adviser to Jounce Therapeutics and currently serves as the alumni endowed professor of pathology and immunology, professor of molecular microbiology, co-leader of the tumor immunology program for the Siteman Comprehensive Cancer Center, and director of the Center for Human Immunology and Immunotherapy Programs (CHiiPs) at Washington University School of Medicine in St. Louis. He is an associate director of the Cancer Research Institute, a member of the U.S. National Academy of Sciences and the American Academy of Arts and Sciences, a fellow of the American Association of Science, a past member of the board of scientific advisers for the National Cancer Institute, and a past president of the Society for Leukocyte Biology.

Dr. Schreiber has led a major revision in our understanding of how the immune system interacts with cancer. His work formed the basis for the concept of cancer immunoediting that helped reveal that the immune system is not only capable of destroying cancers but can sometimes also either hold cancers in a dormant state or sculpt their immunogenicity thereby enhancing their malignancy. His lab is highly regarded for its research on the molecular cell biology and immunology of interferon-gamma and its receptor, as well as its strong expertise in mAb discovery. Dr. Schreiber’s group unequivocally demonstrated that the immune system provides an extrinsic tumor suppressor function (cancer immunosurveillance) capable of eliminating spontaneous and carcinogen-induced primary tumors. He has authored more than 300 peer reviewed and invited publications and has received several honors, including the Milstein Award for Outstanding Achievements in Research on Interferon and Cytokines from the International Society of Interferon and Cytokine Research, the Bonazinga Award for Excellence in Leukocyte Biology Research from the Society for Leukocyte Biology, the William B. Coley Award for Distinguished Research in Basic and Tumor Immunology from the Cancer Research Institute, the Charles Rodolphe Brupbacher Award for Cancer Research from the Brupbacher Cancer Foundation in Switzerland and the AACR-CRI Lloyd J. Old Award in Cancer Immunology awarded jointly by the American Association for Cancer Research and Cancer Research Institute.